Restoring tumor immunogenicity with dendritic cell reprogramming

Area of Science:

• Immunology
• Cancer Biology
• Cellular Reprogramming

Background:

• Cancer cells evade immune detection partly due to decreased antigen presentation.
• Dendritic cells are crucial for initiating adaptive immune responses against tumors.

Purpose of the Study:

• To reprogram cancer cells into professional antigen-presenting cells (tumor-APCs).
• To investigate the therapeutic potential of tumor-APCs in cancer immunotherapy.

Main Methods:

• Utilized the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1).
• Enforced expression of transcription factors PU.1, IRF8, and BATF3 (PIB) in 36 cancer cell lines.
• Assessed transcriptional, epigenetic, and functional changes in reprogrammed tumor-APCs.

Main Results:

• Reprogramming induced cDC1 phenotype, restoring antigen presentation complexes and costimulatory molecules.
• Tumor-APCs enhanced endogenous antigen presentation on MHC-I, activating CD8+ T cells.
• Reprogrammed cells showed impaired tumorigenicity, delayed tumor growth, and increased survival in vivo.
• Tumor-APCs demonstrated synergistic effects with immune checkpoint inhibitors.

Conclusions:

• Reprogramming cancer cells into tumor-APCs is a viable strategy to enhance anti-tumor immunity.
• This approach offers a platform for developing novel immunotherapies targeting endogenous tumor antigens.
• Tumor-APCs can be generated from both hematological and solid tumors, including primary human cells.